GVR Report cover Breast Cancer Imaging Market (2026 - 2033)Report

Breast Cancer Imaging Market (2026 - 2033)

Size, Share & Trends Analysis Report By Stage of Care (Diagnostic, Monitoring), By End Use (Hospitals, Breast Care Centers), By Technology (Mammography System (2D,3D), Nuclear Medicine- Based Systems), By Region, And Segment Forecasts

Market Size, 2025

$2.2B

Market Estimate, 2026

$2.3B

Market Forecast, 2033

$4.0B

CAGR, 2026–2033

8.0%

Breast Cancer Imaging Market Summary

The global breast cancer imaging market size was valued at USD 2.2 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 4.0 billion by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 36.1% in 2025. This growth is attributed to increasing breast cancer awareness, technological advancements, rising incidence rates, and growing government and healthcare initiatives. Breast cancer is the most common type of cancer among women globally.

Breast cancer imaging market overview: Grand View Research estimates the global market size at USD 2.2 billion in 2025, projected to grow from USD 2.3 billion in 2026 to USD 4 billion by 2033 at a 8.0% CAGR, with regional growth momentum.Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, icon Download Free Sample Report

Key Market Trends & Insights

  • By stage of cancer: Diagnostic segment dominated the market, with a revenue share of 33.4% in 2025.
  • By technology: Mammography systems segment held the largest market share of 38.4% in 2025.
  • By end use: Hospitals segment held the largest revenue share of 33.9% in 2025.

Regional Highlights

  • Largest regional market: North America (36.1% revenue share, 2025)
  • Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
  • By country: The U.S. held the largest market share in 2025.

Market Size & Forecast

  • Market size in 2025: USD 2.2 Billion
  • Estimated market size in 2026: USD 2.3 Billion
  • Projected market size by 2033: USD 4.0 Billion
  • CAGR (2026-2033): 8.0%
Ask a question about the breast cancer imaging market
Try asking
✓Every figure cited from GVR research Prefer the report? Download free sample →


In the U.S. alone, an estimated 316,950 women are expected to be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of ductal carcinoma in situ (DCIS), a non-invasive form of the disease. This tendency is forecasted to escalate, for instance, the article by the Lancet Oncology states that global breast cancer incidence is expected to increase by 38% and related deaths by 68% by 2050, highlighting the need for early detection and tracking.

Breast cancer imaging market size and growth forecast (2023-2033)

To learn more about this report, icon Download Free Sample Report

In the U.S., breast cancer is the second most common cancer and the second most common cause of cancer death among women. Contributing factors to the global rise of breast cancer include genetic risk factors, like the BRCA1 and BRCA2 mutations, and lifestyle factors like obesity, poor diet, sedentary lifestyle, smoking, and alcohol consumption. With the escalating severity of this situation, there is an urgent need for effective breast cancer imaging technologies to support timely diagnosis, assess the disease process accurately, and improve patient outcomes, which are crucial for reducing breast cancer mortality rates and managing the global rise in cases.

Technological advancement is another driving factor for the market, leading to a demand for improved diagnostic modalities. While traditional methods like mammography have been the foundation for breast cancer screening, emerging technologies are now complementing these approaches for high-risk populations and dense breast tissue. For example, tomosynthesis (3D mammography) has reduced breast tissue overlap artifacts, increasing cancer detection by 30-40% and decreasing recall rates. Contrast-enhanced spectral mammography (CESM) uses iodine contrast to visualize tumor vascularization in the breast. It performs with diagnostic accuracy like breast MRI for intraductal and lobular carcinomas and for occult lesions. In addition, automated 3D ultrasounds improve reproducibility and detect mammographically occult cancers. Contrast-enhanced ultrasound (CEUS) utilizes microbubbles to enhance the detection of tumor vascularity, similarly to CESM.

In addition, Government and healthcare initiatives contribute to the growth of breast cancer imaging in multiple areas, especially by improving early detection, ensuring screening access, and driving technological innovation. For instance, the National Health Mission (NHM) by the Indian government announced several national programs aimed at tackling breast cancer. The program includes comprehensive breast screening for individuals aged 30+, at Ayushman Arogya Mandirs, with over 14 crore women screened for breast cancer sc. Moreover, the government has approved the establishment of 19 state cancer institutes and 20 tertiary cancer care centers to improve tertiary-level cancer care. Similarly, the U.S. has implemented the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to provide free or low-cost breast and cervical cancer screening and diagnostic services for uninsured or underinsured women. Furthermore, the Centers for Disease Control and Prevention (CDC) collaborates with public, non-profit, and private partners to address breast cancer in women under 45, focusing on prevention, early detection, and education. In addition, the UK government has started a breast screening program, inviting all women aged 50 to 71 to be screened with mammography on a three-yearly basis. The National Health Service Breast Screening Programme supports women in being informed and involved in decision-making around their screening options. These systems of governmental and healthcare-led intervention combine to stimulate demand for technologies that can advance the imaging of breast cancer, thus enabling earlier diagnosis and better outcomes for patients globally.

Market Dynamics

The breast cancer imaging market is experiencing substantial growth due to the emphasis placed by various health care systems on early cancer detection, precision diagnosis, and treatment planning to achieve improved outcomes. Breast cancer imaging consists of several diagnostic tools that help in detecting, characterizing, localizing, and monitoring breast lesions through the patient's care process. There are various imaging modalities used in breast imaging such as mammography systems, MRI-based systems, nuclear medicine-based systems, ultrasound-based systems, image-guided biopsy systems, and other breast imaging modalities. Breast cancer imaging is used in diagnostic assessment, treatment planning, treatment monitoring, and post-treatment surveillance. Increased incidence rates of breast cancer, expansion of population-based screening initiatives, increased awareness about early diagnosis, and ongoing innovations in breast imaging technologies are some of the factors behind the growth of the market. Advancements in digital breast tomosynthesis (DBT), contrast-enhanced mammography, abbreviated breast MRI, artificial intelligence-based image interpretation, molecular breast imaging, automated breast ultrasound, and minimally invasive image-guided biopsy technologies have played a crucial role in improving the process of detection and management of breast cancer.

Increasing global incidence rates of breast cancer and growing applications of breast cancer screening services are the two main factors fueling the growth of the breast cancer imaging market. There are growing applications of imaging techniques by healthcare providers as an effort to detect tumors earlier, characterize lesions, and perform biopsies. Awareness about regular screenings for breast cancer, increased coverage of reimbursement for imaging procedures, and personalization of oncology care are some other factors influencing the demand from hospitals and specialized breast imaging centers. Advancements in artificial intelligence-enabled mammography, digital breast tomosynthesis, contrast enhanced imaging, and multi-modal breast imaging techniques have further fueled demand for imaging procedures.

Despite continuous technological advancements, adoption of advanced breast cancer imaging systems remains constrained owing to high capital acquisition costs, infrastructure requirements, and disparities in access to specialized imaging services. Advanced technologies such as breast MRI, molecular breast imaging, DBT, and contrast-enhanced imaging require significant investments in equipment, software, facility upgrades, and specialized radiology expertise. Moreover, limited reimbursement coverage, shortage of skilled breast imaging specialists, and irregularly distributed access to organized screening programs in low- and middle-income regions may restrict widespread utilization of advanced breast imaging technologies.

 

Market Concentration & Characteristics

The market for breast cancer imaging is seeing robust growth propelled by technology, increasing cases of breast cancer, and increased awareness of early detection. New emerging companies like Delphinus Medical Technologies, with its SoftVue 3D Entire Breast Ultrasound Tomography System, and QT Imaging's QT Breast Acoustic CT, are bringing advanced imaging technology to the market, both of which provide non-invasive, high-resolution breast imaging systems with a greater capability to detect breast cancer and other anomalies. Market growth is also rising due to established companies like GE Healthcare and Hologic Inc. These companies are improving the accuracy and accessibility of breast cancer detection technology with AI-driven diagnostics approaches, 3D mammography, and automated imaging systems.

Breast cancer imaging is experiencing robust innovation, shifting from traditional mammography to digital mammograms, 3D imaging, breast MRIs, and AI-assisted mammographic reading that enhances early and accurate tumor detection, particularly with denser breast tissue. AI algorithms enhance radiologists' ability to find areas of potential concern and minimize missed diagnoses and false positive rates. Liquid biopsies and circulating tumor DNA (ctDNA) assays are emerging tools for non-invasive early detection and personalized follow-up.

Breast Cancer Imaging Industry Dynamics

To learn more about this report, icon Download Free Sample Report

Partnerships and collaborations are increasingly shaping the market by enabling technological access and enhancing diagnostic accuracy. For instance, in May 2025, RamSoft's partnership with Therapixel makes it possible to incorporate the AI-powered MammoScreen software directly into RamSoft's PowerServer and OmegaAI platforms, allowing radiologiststo detect breast cancer better, characterize lesions, and improve workflow efficiencies using AI-based tools. Similarly, in June 2025, B-RayZ's collaboration with Affidea is significant in the advancement of integrating AI-enabled capabilities in clinical breast imaging. This partnership will enable Affidea to deploy B-RayZ AI-based breast imaging platforms, thereby allowing the automated analysis of mammograms, increased screening accuracy, and earlier breast cancer detection in its diagnostic centers. Overall, these collaborations demonstrate how AI and imaging analytics are improving the accuracy of diagnostic mammography, streamlining workflow, and helping develop innovation in breast cancer imaging.

The breast cancer imaging industry is governed by strict regulatory requirements designed to guarantee diagnostic device safety, effectiveness, and quality. In the U.S., the Mammography Quality Standards Act (MQSA) mandates that all mammography facilities meet uniform quality standards, including certification, accreditation, annual inspections, following personnel requirements, and adhering to equipment specifications. Amended in 2023, the MQSA rules establish federal quality standards for mammography services and require facility compliance.

Over certain traditional methods, new breast cancer diagnostic methods are also emerging. Methods like non-image-guided, such as fine-needle aspiration (FNA), provide a less invasive approach to tissue or fluid analysis by allowing sampling of palpable masses without imaging. Along with traditional biopsy methods, these procedures are espousing early detection, accurate diagnosis, and patient convenience, enabling more efficient and tailored treatment for breast cancer.

The breast cancer imaging industry's growth is supported by regional growth that expands access to advanced diagnostic services and early detection solutions. North America & Europe are the dominant regions based on high levels of investment in healthcare, an established screening program, and additional infrastructure. Conversely, the Asia Pacific region is experiencing growth due to the increased incidence of breast cancer, rising awareness, and development of healthcare infrastructure. Growth continues through strategic investment, partnerships, and collaborations, while initiatives such as the Bayer and Hologic partnership to offer contrast-enhanced mammography solutions, government screening program initiatives, and AI that will incorporate imaging technologies throughout the clinic system will further support growth.

Analyst Perspective

The breast cancer imaging market is poised to operate positively due to rising adoption of precision oncology, artificial intelligence, and value-based healthcare. The growing importance of early detection, risk-based screening and personalized treatment plans is contributing to the accelerated use of advanced breast imaging technology along the patient care continuum. Companies are increasingly embedding AI-enhanced image analysis, cloud-based workflow management systems, automated lesion detection, quantitative imaging biomarkers and multimodality diagnostics in their offerings to optimize the process and minimize interpretation variability. Besides this, growing spending on breast cancer awareness campaigns, national screening programs and minimally invasive diagnostic procedures is presenting several opportunities for growth in both mature and emerging healthcare markets.

Technology Insights

Based on technology, the mammography systems segment led the market with the largest revenue share of 38.4% in 2025. This is attributed to factors such as high-resolution imaging, cross-sectional imaging, and imaging of breast tissue in three-dimensional modes, critical to detecting and diagnosing breast cancer early in a patient's care, specifically with dense breast tissue. 3D mammograms (tomosynthesis) allow radiologists to visualize the breast tissue in many small layers, improving cancer detection and decreasing the risk for false positives and unneeded biopsies. With technology, there are new 3D imaging options available with new density assessment tools or approaches that improve the accuracy and reliability of breast cancer screening processes. With the speed of imaging and imaging clarity improving, clinical options for mammography expand to allow clinicians to perform a complete and efficient range of diagnostic assessments.

The ultrasound-based systems is witnessing significant growth at a CAGR of 7.7%. Ultrasound is a safe and readily accessible imaging modality that uses high-frequency sound waves to capture live images of breast tissue. It can be especially useful in identifying lesions in dense breast tissue, which may be a limitation in mammography. For instance, in July 2023, researchers at MIT developed and introduced a wearable ultrasound scanner that enables continuous at-home surveillance for early breast cancer detection. Innovations like these highlight the expanding role of ultrasound in enhancing early diagnosis, convenience for patients, and screening evaluation.

Stage of Care Insights

Based on stage of care, the diagnostic segment led the market with the largest revenue share of 33.4% in 2025, because of the increased use of advanced breast imaging methods. Examples of advanced breast imaging include digital mammography, 3D mammography (tomosynthesis), breast MRI, and molecular breast imaging (MBI), which provides better visualization of breast tissue in detail and in multiple planes to aid in detecting and characterizing tumors. The emergence of integrating multiple imaging methods has allowed radiologists to evaluate tumor size, location, and density, as well as monitor disease progression and responses to therapies. The increased reliance on imaging-based diagnostic tools for early detection, risk assessment, and personalized treatment planning and implementation indicates the importance of imaging tools, techniques, and methods in breast cancer care today.

The monitoring segment is witnessing significant growth at a CAGR of 8.1% during the forecast period. Driven by the rising demand for early detection and follow-up of breast cancer. New imaging modalities, including mammography, digital mammography, 3D mammography (tomosynthesis), and breast MRI, enhance the precision and effectiveness of periodic surveillance, which can detect recurrences or new lesions at an early stage. This pattern indicates an increasing reliance on imaging-based surveillance, as well as a growing role for advanced diagnostic equipment in current care for breast cancer.

End Use Insights

Based on end use, the hospitals segment led the market with the largest revenue share of 33.9% in 2025, primarily because of the rapid implementation of advanced diagnostic technologies and hospitals adopting and expanding their screening programs into clinical practice. Hospitals give more benefits because they can provide a diagnosis of breast cancer earlier, when it is more treatable. Patients diagnosed with breast cancer early can often be treated less aggressively and have better outcomes in the long term. Early detection of breast cancer usually leads to a smaller cancer size, no spread to lymph nodes, and the need for less extensive surgery, and not needing chemotherapy, increasing the chances of recovery.

Breast Cancer Imaging Market Share

To learn more about this report, icon Download Free Sample Report

The breast care centers is expected to grow significantly at a CAGR of 7.4% during the forecast period. These centers provide specialized, comprehensive breast imaging services, increasing patient availability and convenience. For instance, the Elizabeth Wende Breast Care (EWBC) facility in Rochester, New York, has grown from a single facility into seven centers in a 200-mile radius. This demonstrates a clear demand for breast cancer screenings. The demand is driven partly by increasing public awareness of breast cancer as well as the importance of early detection.

Regional Insights

North America dominated the breast cancer imaging market with the largest revenue share of 36.1% in 2025. The North American breast cancer imaging market is witnessing significant growth due to the rising number of breast cancer cases and a strong healthcare system. The increase in the number of people with breast cancer, as well as greater awareness and screening programs, is driving the demand for early detection and effective imaging technology. Access to established healthcare systems, clinical sites, and advanced imaging technology allows the use of advanced imaging modalities, including digital mammography, 3D mammography, and breast MRI. Coupled with government programs and healthcare investments, these factors are rapidly growing in the market and driving the advancement of breast cancer imaging in the clinical setting.

Breast Cancer Imaging Market Trends, by Region, 2025 - 2033

To learn more about this report, icon Download Free Sample Report

U.S. Breast Cancer Imaging Market Trends

The breast cancer imaging market in the U.S. held the largest share in the North America region in 2025. The breast cancer imaging market in the U.S. is the fastest-growing market due to the highest number of breast cancer cases across the globe and a strong healthcare infrastructure. According to the National Breast Cancer Foundation, in 2025, an estimated 316,950 women and 2,800 men will be diagnosed with invasive breast cancer. In addition, 59,080 new cases of non-invasive (in situ) breast cancer will be diagnosed. The high rate of incidents demonstrates the necessity for advanced imaging technologies to help find breast cancers at an early stage and to optimize patient outcomes.

Europe Breast Cancer Imaging Market Trends

The breast cancer imaging market in Europe is witnessing significant growth, mainly due to an increase in breast cancer cases resulting from lifestyle changes. There is also an increased consumer interest in accurate diagnosis and treatment planning as patients move more towards advanced imaging types, such as 3D mammography or breast MRI. There are established healthcare infrastructure and government program support in this area, which will also continue to help drive growth.

The UK breast cancer imaging market is steadily growing due to the increased incidence, with breast cancer being the most frequently diagnosed cancer in women; it represents nearly one-third of all new cancer cases diagnosed. Currently, a woman is diagnosed with breast cancer every 9 minutes, and this could rise to every 8 minutes by 2040 without intervention. Gender and age represent the primary risk factors, with 80% of new cases diagnosed in women over the age of 50. Genetics and family history are also risk factors, with 5-10% of breast cancers associated with inherited alterations in genes. In addition, lifestyle modifications can also be made to assist with risk reduction.

The breast cancer imaging market in Germany is witnessing significant growth; many factors drive this. The major factor is the increasing cases and the rising incidence of breast cancer, with high rates of cases occurring in women aged 50 and older, and, adding to these, new technological advancements in diagnostics and treatment are also fueling the market growth. New and improved technologies, such as imaging modalities and personalized treatment advances, are improving the accuracy of diagnosis and delivering appropriate treatment, enhancing the outcome of patients. Growing awareness about breast cancer, as well as proactive screening programs, also contributes to market growth.

Asia Pacific Breast Cancer Imaging Market Trends

The breast cancer imaging market in the Asia Pacific is the fastest-growing, fueled by the rising incidence of breast cancer and the advancement of medical technology. In addition, the region is witnessing a rise in early-onset breast cancer, with a notable share of breast cancer cases being diagnosed in women younger than fifty. Factors contributing to this growing incidence include lifestyle alterations, reproductive patterns, and genetics. To address this growing burden, several regional countries are developing new screening initiatives and using technological advancements to promote early detection and treatment. For instance, India has created an AI-based mobile app to promote early detection of breast cancer, employing data collected from rural and urban India to assess risk and recommend appropriate diagnostic tests. These forms of technological development clearly demonstrate the commitment of the region to mitigate the rising breast cancer burden by implementing technological advancements and improved access to health care.

Japan breast cancer imaging market is witnessing a rise due to evolving, increasing cases, and advances in technology. Japan has seen a greater number of breast cancer cases, particularly among women who are middle-aged and older aged. Breast cancer is a notable contributor to cancer-related deaths in women; therefore, the increase in the burden of breast cancer indicates a need for early diagnosis and treatment. In addition to the increased burden, Japan has implemented innovative screening programs and has adopted advanced imaging technology that is expected to facilitate and promote further market growth.

The breast cancer imaging market in China is rapidly growing. The demand for breast cancer in China is being driven by increasing incidence and advancements in technology. In 2024, an estimated 3,246,625 new cases will be diagnosed. Awareness, lifestyle changes, and reproductive patterns drive this increase in number. New screening initiatives and contemporary diagnostic technology will facilitate early detection and treatment, fueling market development.

India breast cancer imaging market is experiencing a rising demand for breast cancer screening, fueled by strong government support and initiatives. The government has screened 14 crores of individuals for breast cancer through its health programs. Screening is also available for the 30-year-old and above population at Ayushman Arogya Mandirs under the National Health Mission. The government also provides coverage for cancer-related treatment under Ayushman Bharat PM-JAY, with cancer packages available in medical, surgical, radiation, and palliative oncology.

Latin America Breast Cancer Imaging Market Trends

The breast cancer imaging market in Latin America is supported by the rising incidence of breast cancer and increasing awareness of early detection. The region has experienced steady growth in breast cancer cases in recent years, with many women diagnosed at later stages due to limited access to screening and diagnostic facilities. Government initiatives, continuing developments in the healthcare infrastructure, and increased use of advanced imaging and treatment technologies contribute to improved early detection and, as a result, overall patient outcomes. These factors are pulling together to support market growth across the region.

Brazil breast cancer imaging market is experiencing significant growth, with growing incidence and mortality rates being the main factors driving the market. Breast cancer is the most common cancer among women in the nation. In Brazil, approximately 74,000 new cases of breast cancer are expected during the 2023-2025 period, underscoring the growing need for effective screening and diagnostic services. Breast cancer is also the most common cause of cancer-related deaths among Brazilian women. To address this expanding public health concern, improved screening, early detection, and treatment approaches are required, as evidenced by the rising incidence and mortality rates.

Middle East & Africa Breast Cancer Imaging Market Trends

The breast cancer imaging market in the Middle East & Africa is rapidly expanding. The Middle East and Africa market is driven by rising incidence and growing initiatives to improve care. A recent analysis across nine countries-including Saudi Arabia, UAE, Egypt, and South Africa-highlights challenges in detection, diagnosis, and treatment, with variations in healthcare access and infrastructure. The WHO Global Breast Cancer Initiative framework is being adopted to strengthen early detection, diagnostic accuracy, and treatment pathways. Tailored national strategies and expert-recommended interventions are expected to enhance patient outcomes and support market growth in these regions.

Saudi Arabia breast cancer imaging market is expected to grow in the forecast period. Government-led efforts to enhance early detection and treatment, as well as rising incidence and awareness, are driving the market for breast cancer.  The adoption of cutting-edge diagnostic technologies and growing healthcare infrastructure facilitates better patient outcomes and market expansion.

The breast cancer imaging market in Kuwait is expected to grow steadily. Growing awareness and rising incidence rates are driving the market. Government-led programs like the National Mammography Screening Program aim to enhance early detection and treatment. The adoption of cutting-edge diagnostic technologies and growing healthcare infrastructure facilitates better patient outcomes and market expansion.

Key Breast Cancer Imaging Company Insights

The market is highly competitive, with key players such as GE Healthcare, Hologic Inc., and Siemens Healthcare. The major companies undertake various organic and inorganic strategies, such as product introduction, collaborations, and regional expansion, to serve their customers' unmet needs.

Key Breast Cancer Imaging Companies

The following key companies have been profiled for this study on the breast cancer imaging market.

  • GE Healthcare

  • Hologic Inc.

  • Siemens healthcare

  • Philips Healthcare

  • Delphinus Medical Technologies

  • Trivitron Healthineers

  • Aurora Imaging Technology Inc.

  • Micrima Limited

  • QT Ultrasound LLC

  • Fujifilm

Competitive Benchmarking

Category

Operating Strategies

Competitive Edge

Weakness

Established Players (GE HealthCare, Hologic Inc., Siemens Healthineers, Philips Healthcare, Fujifilm, Carl Zeiss Meditec AG)

  • Established companies focus on comprehensive breast imaging portfolios comprising digital mammography, digital breast tomosynthesis, breast MRI, ultrasound, image-guided biopsy solutions, AI-enabled diagnostic software, and integrated oncology imaging platforms. They emphasize continuous technological innovation, AI-assisted image interpretation, workflow automation, strategic hospital partnerships, and expansion of women's health imaging portfolios to maintain market leadership.
  • Extensive global distribution networks, strong installed equipment base, broad diagnostic imaging portfolios, advanced AI capabilities, and established relationships with hospitals, imaging centers, and breast care programs. Significant financial resources support continuous R&D, regulatory compliance, and large-scale manufacturing.
  • Dependence on hospital capital equipment purchasing cycles, lengthy procurement processes, pricing pressure from healthcare cost-containment initiatives, and increasing competition from emerging imaging innovators may affect growth. Large organizational structures may also reduce agility in rapidly commercializing niche imaging technologies.

Emerging Players (Delphinus Medical Technologies, Trivitron Healthineers, Aurora Imaging Technology Inc., Micrima Limited, QT Ultrasound LLC)

  • Emerging companies prioritize innovative breast imaging technologies including automated breast ultrasound, dedicated breast MRI, microwave imaging, transmission ultrasound, and affordable diagnostic solutions targeting unmet clinical needs. They focus on technological differentiation, regional expansion, strategic collaborations, and improving accessibility to advanced breast imaging.
  • Agile product development, specialized breast imaging expertise, differentiated technologies, and ability to address niche clinical applications such as dense breast imaging and radiation-free diagnostic solutions. Flexible commercialization strategies support expansion into emerging healthcare markets.
  • Limited global commercial infrastructure, smaller installed base, lower brand recognition, and restricted financial resources compared with multinational imaging manufacturers. Regulatory approval timelines and dependence on distributor partnerships may slow global market penetration.

Get access to detailed company insights of key market participants. To know more request a free sample copy

Recent Developments

  • On 15 October 2025, Fujifilm and Beekley Medical hosted the 2nd Annual Breast Imaging Education Summit

  • On 16 September 2025, Molbio Diagnostics partners with UE LifeSciences to expand early breast cancer detection in over 50 developing countries

  • In April 2025, b-rayZ and Medecom forged a strategic alliance to enhance AI-powered breast cancer diagnostics.

  • In April 2025, GE HealthCare showcased the latest advancements in diagnostic accuracy and patient-centered breast care at the SBI 2025 Breast Cancer Imaging Symposium.

Breast Cancer Imaging Market Report Scope

Report Attribute

Details

Market size in 2025

USD 2.2 billion

Estimated market size in 2026

USD 2.3 billion

Projected market size by 2033

USD 4.0 billion

Growth rate

CAGR of 8.0% from 2026 to 2033

Historical data

2021 - 2024

Forecast period

2026 - 2033

Quantitative units

Revenue in USD million/billion and CAGR from 2026 to 2033

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Technology, stage of care, end use region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Thailand; Australia; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

GE Healthcare; Hologic Inc.; Siemens healthcare; Philips Healthcare; Delphinus Medical Technologies; Trivitron Healthineers; Aurora Imaging Technology Inc.; Micrima Limited; QT Ultrasound LLC; Fujifilm.

Customization scope

Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Breast Cancer Imaging Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast cancer imaging market report based on technology, stage of care, end-use, and region:

Global Breast Cancer Imaging Market Report Segmentation

To learn more about this report, icon Download Free Sample Report

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)

    • Mammography System (2D,3D)

    • Magnetic Resonance Imaging (MRI)-based systems

    • Nuclear Medicine- Based Systems

    • Ultrasound-Based Systems

    • Image-guided Biopsy

    • Others

  • Stage of Care Outlook (Revenue, USD Million, 2021 - 2033)

    • Diagnostics

    • Pre-treatment Planning

    • Monitoring

    • Surveillance (Follow-Up)

  • End Use Outlook (Revenue, USD Million, 2021 - 2033)

    • Hospitals

    • Diagnostic Imaging Centers

    • Breast Care Centers

    • Others

  • Region Outlook (Revenue, USD Million, 2021 - 2033)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Research Methodology

The breast cancer imaging market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each breast cancer imaging segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Technology

Revenue capture definition

Mammography Systems

Revenue is generated through the commercialization of digital mammography systems, digital breast tomosynthesis (3D mammography), contrast-enhanced mammography systems, software upgrades, detectors, and associated service contracts utilized for routine breast cancer screening and diagnostic imaging. This segment represents the largest contributor to market revenue due to widespread adoption in national screening programs.

Magnetic Resonance Imaging (MRI)–Based Systems

Revenue is derived from breast MRI systems and dedicated breast imaging solutions utilized for high-risk screening, lesion characterization, preoperative staging, treatment response assessment, and surveillance. Manufacturers benefit from premium imaging systems, advanced software applications, and contrast-enhanced breast MRI technologies.

Nuclear Medicine–Based Systems

Revenue is generated through molecular breast imaging (MBI), breast-specific gamma imaging (BSGI), positron emission mammography (PEM), and other nuclear imaging technologies utilized for functional assessment of breast lesions and adjunctive breast cancer diagnosis.

Ultrasound-Based Systems

Revenue is captured through handheld ultrasound, automated breast ultrasound (ABUS), and high-resolution breast ultrasound systems utilized for supplemental screening, lesion characterization, biopsy guidance, and evaluation of dense breast tissue.

Image-guided Biopsy

Revenue is generated through stereotactic biopsy systems, ultrasound-guided biopsy systems, MRI-guided biopsy equipment, vacuum-assisted biopsy devices, localization technologies, and associated disposable biopsy consumables utilized for minimally invasive tissue sampling.

Others

Revenue is derived from emerging breast imaging technologies including optical imaging, elastography, molecular imaging innovations, AI-enabled imaging software, and other specialized diagnostic technologies supporting breast cancer detection and management.

Stage of Care

Revenue capture definition

Diagnostic

Revenue is generated through utilization of breast imaging technologies for initial detection, diagnostic workup, lesion characterization, and confirmation of suspected breast abnormalities identified during screening or clinical examination. This segment contributes the largest share owing to the high volume of diagnostic imaging procedures.

Pre-treatment Planning

Revenue is derived from advanced imaging utilized to assess tumor size, multifocal disease, lymph node involvement, treatment eligibility, surgical planning, and radiation therapy planning prior to therapeutic intervention.

Monitoring

Revenue is generated through serial imaging performed to evaluate treatment response during chemotherapy, neoadjuvant therapy, targeted therapy, immunotherapy, or radiation therapy. Manufacturers benefit from increasing adoption of imaging biomarkers and precision oncology treatment monitoring.

Surveillance (Follow-Up)

Revenue is captured through routine post-treatment imaging utilized to detect disease recurrence, evaluate treatment outcomes, monitor long-term survivors, and support ongoing breast cancer management following completion of therapy.

End Use

Revenue capture definition

Hospitals

Revenue is generated through procurement and utilization of breast imaging systems by public and private hospitals providing comprehensive breast cancer screening, diagnosis, biopsy, treatment planning, and oncology services. Manufacturers benefit from capital equipment sales, software upgrades, maintenance contracts, and imaging accessories.

Diagnostic Imaging Centers

Revenue is derived from specialized outpatient imaging centers performing screening mammography, breast ultrasound, breast MRI, image-guided biopsy, and diagnostic breast imaging services. Growing patient referrals and expansion of outpatient diagnostic services support recurring demand.

Breast Care Centers

Revenue is generated through dedicated breast centers offering multidisciplinary breast cancer screening, diagnosis, image-guided interventions, personalized treatment planning, and survivorship care utilizing advanced multimodality imaging technologies.

Others

Revenue is captured through adoption by academic medical centers, cancer institutes, ambulatory surgical centers, mobile breast screening units, research organizations, and government screening programs utilizing breast imaging technologies.

Estimation Model

Step

Guiding Question

Process Steps

Data Sources

Step 01: Scope Definition

What is being studied?

Define Breast Cancer Imaging Technology Scope.

Scope Technology, Stage of Care, and End-use Segments.

Establish Geographic Coverage (Global/Regional).

Align to year & forecast horizon (2018–2033).

FDA, M&A Database, EMA, ACR

Step 02: Build the Procedure Volume

How large is total addressable market?

Estimate Annual Breast Cancer Screening and Diagnostic Imaging Procedure Volumes.

Segment Procedure Volumes by Imaging Modality.

Assess Imaging Utilization across Different Stages of Care.

Forecast Growth by Breast Cancer Incidence, Screening Participation Rates, Population Demographics, and Technology Adoption.

National Cancer Registries, WHO, IARC (GLOBOCAN), National Breast Cancer Screening Programs

Step 03: Estimate Product Utilization

What proportion undergoes breast imaging?

Estimate Annual Breast Imaging Procedures by Modality.

Assess Utilization Across Stage of Care.

Analyze Repeat Treatment Cycles and Product Longevity.

Validate Through Industry Interviews.

Industry interviews, clinical surveys, industry reports

Step 04: Revenue Conversion

How does volume become revenue?

Determine ASPs by Imaging Modality and Region.

Estimate Revenue from Equipment Sales.

Apply Regional Pricing Variations.

Cross-validate with Company Revenues and Public Filings.

Company financials, Distributor pricing sheets, Procurement data, Expert interviews

Delivered Customizations

This report has been delivered with the following In-depth customizations

Client Request

Customization Delivered

Value Adds

Competitive Landscape Analysis

Conducted a comprehensive competitive assessment of the global breast cancer imaging market, evaluating leading manufacturers across mammography, breast MRI, ultrasound, nuclear medicine imaging, image‑guided biopsy systems, and AI‑enabled breast imaging software. The study assessed product portfolios, imaging technologies, detector innovations, software capabilities, regulatory approvals, pricing strategies, distribution networks, clinical partnerships, and technological advancements supporting precision breast cancer diagnosis.

Enables stakeholders to understand technology leadership, competitive positioning, commercialization strategies, innovation trends, and procurement dynamics shaping the global breast cancer imaging market. Supports vendor benchmarking, partnership evaluation, investment planning, and product differentiation strategies.

Segment by Application Analysis

Conducted a detailed assessment across Mammography Systems, MRI‑Based Systems, Nuclear Medicine‑Based Systems, Ultrasound‑Based Systems, Image‑guided Biopsy, and other technologies while evaluating Diagnostic, Pre‑Treatment Planning, Monitoring, and Surveillance stages of care. The study analyzed imaging volumes, technology adoption, clinical utilization, reimbursement trends, workflow requirements, and forecast demand across each segment.

Enables stakeholders to identify high‑growth imaging modalities, optimize product portfolios, develop commercialization strategies, align technology development with evolving clinical pathways, and identify emerging opportunities in precision breast cancer management.

Macroeconomic Analysis

Conducted an in‑depth assessment of breast cancer incidence, national screening initiatives, healthcare expenditure, diagnostic imaging investments, aging demographics, reimbursement policies, oncology infrastructure, regulatory developments, AI adoption, and government funding programs influencing breast cancer imaging demand globally.

Enables stakeholders to understand the macroeconomic, demographic, regulatory, and healthcare system factors impacting breast cancer imaging demand across the global market. The study supports long‑term forecasting, investment prioritization, manufacturing capacity planning, and market entry strategies in the rapidly evolving oncology imaging landscape.

Frequently Asked Questions About This Report

About the Author(s)

Medical Devices Research Team

Healthcare · Medical Devices

This report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.

Last Updated:

Speak to Analyst

Trusted market insights - try a free sample

See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.

logo
GDPR & CCPA Compliant
logo
ISO 9001 Certified
logo
ISO 27001 Certified
logo
ESOMAR Member
Grand View Research is trusted by industry leaders worldwide
client logo
client logo
client logo
client logo
client logo
client logo